Masayuki Sho

14.4k total citations · 4 hit papers
296 papers, 9.9k citations indexed

About

Masayuki Sho is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Masayuki Sho has authored 296 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 178 papers in Oncology, 135 papers in Surgery and 94 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Masayuki Sho's work include Pancreatic and Hepatic Oncology Research (117 papers), Pancreatitis Pathology and Treatment (44 papers) and Neuroendocrine Tumor Research Advances (35 papers). Masayuki Sho is often cited by papers focused on Pancreatic and Hepatic Oncology Research (117 papers), Pancreatitis Pathology and Treatment (44 papers) and Neuroendocrine Tumor Research Advances (35 papers). Masayuki Sho collaborates with scholars based in Japan, United States and China. Masayuki Sho's co-authors include Yoshiyuki Nakajima, Hideo Yagita∥, Takahiro Akahori, Ichiro Yamato, Hiromichi Kanehiro, Mohamed H. Sayegh, Takeo Nomi, Naoya Ikeda, Sohei Satoi and Kaoru Hamada and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Masayuki Sho

271 papers receiving 9.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

2007 729 citations Takeo Nomi, Masayuki Sho et al. Clinical Cancer Research profile →
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

2009 663 citations Qiang Gao, Xiaoying Wang et al. Clinical Cancer Research profile →
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

2005 660 citations Masayuki Sho, Naoya Ikeda et al. Clinical Cancer Research profile →
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)

2018 379 citations Fuyuhiko Motoi, Tomoo Kosuge et al. profile →

Peers

Countries citing papers authored by Masayuki Sho

Since Specialization

Citations

This map shows the geographic impact of Masayuki Sho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masayuki Sho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masayuki Sho more than expected).

Fields of papers citing papers by Masayuki Sho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masayuki Sho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masayuki Sho. The network helps show where Masayuki Sho may publish in the future.

Co-authorship network of co-authors of Masayuki Sho

This figure shows the co-authorship network connecting the top 25 collaborators of Masayuki Sho. A scholar is included among the top collaborators of Masayuki Sho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masayuki Sho. Masayuki Sho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer 2025 ·Annals of Surgery ·Michiaki Unno, Fuyuhiko Motoi, Yutaka Matsuyama, (unknown), Hirochika Toyama, Ippei Matsumoto, Suefumi Aosasa, Hirofumi Shirakawa, Keita Wada, Tsutomu Fujii, Hideyuki Yoshitomi, Shinichiro Takahashi, Masayuki Sho, Hideki Ueno, Tomoo Kosuge	7
2	Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma 2024 ·Pancreatology ·(unknown), Satoshi Nishiwada, Minako Nagai, Kota Nakamura, (unknown), Satoshi Yasuda, (unknown), (unknown), Takeshi Sakata, (unknown), (unknown), Masayuki Sho	1
3	Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma 2024 ·International Journal of Molecular Sciences ·Rina Fujiwara‐Tani, Takamitsu Sasaki, Ujjal K. Bhawal, Shiori Mori, (unknown), Rika Sasaki, (unknown), Shingo Kishi, Kiyomu Fujii, Hitoshi Ohmori, Masayuki Sho, Hiroki Kuniyasu	3
4	Central pancreatectomy might be an acceptable surgical procedure for clinical T1 pancreatic body ductal adenocarcinoma: A multicenter retrospective analysis 2023 ·Journal of Hepato-Biliary-Pancreatic Sciences ·(unknown), Manabu Kawai, Yuji Kitahata, Sohei Satoi, Daisuke Hashimoto, Minako Nagai, Satoshi Nishiwada, Tomohisa Yamamoto, Hiroki Yamaue, Masayuki Sho	2
5	Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma 2023 ·International Journal of Molecular Sciences ·(unknown), Rina Fujiwara‐Tani, Shiori Mori, Shingo Kishi, Yukiko Nishiguchi, Takamitsu Sasaki, (unknown), (unknown), Rika Sasaki, Hitoshi Ohmori, Yi Luo, Ujjal K. Bhawal, Masayuki Sho, Hiroki Kuniyasu	15
6	Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma 2023 ·Annals of Gastroenterological Surgery ·Satoshi Yasuda, Minako Nagai, (unknown), (unknown), Masayuki Sho	12
7	Liver metastases of a neuroendocrine tumor arising from a tailgut cyst treated with interventional locoregional therapies: a case report and review of the literature on recurrent cases 2022 ·International Cancer Conference Journal ·(unknown), Fumikazu Koyama, Hiroyuki Kuge, Shinsaku Obara, (unknown), (unknown), (unknown), (unknown), (unknown), Tomoko Uchiyama, Chiho Ohbayashi, Hideyuki Nishiofuku, Toshihiro Tanaka, Masayuki Sho	1
8	A case of Cronkhite–Canada syndrome with repeated linked color imaging observation of the subepithelial capillary network in the colon 2022 ·Clinical Journal of Gastroenterology ·(unknown), Fumikazu Koyama, Kohei Morita, Hiroyuki Kuge, Shinsaku Obara, (unknown), (unknown), (unknown), Chiho Ohbayashi, Masayuki Sho	1
9	Serrated polyposis syndrome with multiple inverted lesions in the colon: Case report and elucidation of morphogenetic mechanism 2021 ·SHILAP Revista de lepidopterología ·(unknown), Fumikazu Koyama, Kohei Morita, Hiroyuki Kuge, Takayuki Nakamoto, Shinsaku Obara, (unknown), Tomohiro Kunishige, Chiho Ohbayashi, Masayuki Sho	0
10	The middle rectal artery detected by contrast-enhanced magnetic resonance imaging predicts lateral lymph node metastasis in lower rectal cancer 2021 ·International Journal of Colorectal Disease ·(unknown), Fumikazu Koyama, Nagaaki Marugami, Hiroyuki Kuge, Takayuki Nakamoto, Shinsaku Obara, Satoshi Nishiwada, (unknown), (unknown), Satoshi Yamauchi, Kimihiko Kichikawa, Masayuki Sho	7
11	The existence of an endoscopically observable capillary plexus in the deep colonic mucosa 2021 ·Endoscopy ·Fumikazu Koyama, Takeshi Ueda, Kohei Morita, Hisao Fujii, (unknown), Chiho Obayashi, Masayuki Sho	1
12	In vitro analysis of exfoliated tumor cells in intraluminal lavage samples after colorectal endoscopic submucosal dissection 2021 ·International Journal of Colorectal Disease ·Takayuki Nakamoto, Fumikazu Koyama, Hiroyuki Kuge, Shinsaku Obara, Naoya Ikeda, (unknown), (unknown), (unknown), (unknown), Kosuke Fujimoto, Takashi Inoue, Kinta Hatakeyama, Chiho Ohbayashi, Masayuki Sho	1
13	Does anatomic resection improve the postoperative outcomes of solitary hepatocellular carcinomas located on the liver surface? 2017 ·Surgery ·Daisuke Hokuto, Takeo Nomi, Satoshi Yasuda, Takahiro Yoshikawa, (unknown), Takatsugu Yamada, Takahiro Akahori, Kenji Nakagawa, Minako Nagai, Kota Nakamura, Hiromichi Kanehiro, Masayuki Sho	15
14	Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma breakdown → 2009 ·Clinical Cancer Research ·Qiang Gao, Xiaoying Wang, Shuang‐Jian Qiu, Ichiro Yamato, Masayuki Sho, Yoshiyuki Nakajima, Jian Zhou, Baizhou Li, Yongyong Shi, Yongsheng Xiao, Yang Xu, Jia Fan	663
15	A Case of Thrombotic Thrombocytopenic Purpura Related to Late-onset Pancreatic Fistula after Pancreaticoduodenectomy 2007 ·The Japanese Journal of Gastroenterological Surgery ·Takeo Nomi, Masayuki Sho, (unknown), Yoshiyuki Nakajima	1
16	Clinical significance and therapeutic potential of PD-L/PD-1 pathway in human pancreatic cancer 2006 ·Cancer Research ·Takeo Nomi, Masayuki Sho, Takahiro Akahori, Kaoru Hamada, Hiromichi Kanehiro, Michiyoshi Hisanaga, Naoya Ikeda, Miyuki Azuma, Yoshiyuki Nakajima	2
17	The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity 2003 ·Journal of Clinical Investigation ·Hiroshi Harada, Alan D. Salama, Masayuki Sho, Atsushi Izawa, Sigrid Sandner, Toshiro Ito, Hisaya Akiba, Hideo Yagita∥, Arlene H. Sharpe, Gordon J. Freeman, Mohamed H. Sayegh	117
18	Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance 2002 ·Journal of Clinical Investigation ·Koji Kishimoto, Sigrid Sandner, Jaime Imitola, Masayuki Sho, Yongsheng Li, Peter Langmuir, David M. Rothstein, Terry B. Strom, Laurence A. Turka, Mohamed H. Sayegh	57
19	Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance 2002 ·Journal of Clinical Investigation ·Koji Kishimoto, Sigrid Sandner, Jaime Imitola, Masayuki Sho, Yongsheng Li, Peter Langmuir, David M. Rothstein, Terry B. Strom, Laurence A. Turka, Mohamed H. Sayegh	4
20	The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo 2000 ·Journal of Clinical Investigation ·Koji Kishimoto, Victor Dong, Shohreh Issazadeh‐Navikas, Eugenia V. Fedoseyeva, Ana Maria Waaga, Akira Yamada, Masayuki Sho, Gilles Bénichou, Hugh Auchincloss, Michael J. Grusby, Samia J. Khoury, Mohamed H. Sayegh	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact